CRIS.US Curis Inc

Healthcare Biotechnology USA Stocks
0.4450 USD
Close of Nov 13, 2026
0.3300 28.40
Market cap
USD 2.97M
P/E
0.4x
P/B
0.30x
ROE
-2,137.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is CRIS.US undervalued?

Graham number

The Graham number of Curis Inc cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Curis Inc fundamental analysis

No fundamental analysis for Curis Inc yet.

Curis Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Curis Inc

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed/refractory primary central nervous system lymphoma. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDA…

Full company profile